Office-use compounding in Pennsylvania

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

This is the whole state standardHigh confidence

One sentence, and it is a conduit rather than a rule. Adopted June 21, 2019, effective June 22, 2019, 49 Pa.B. 3210 — confirmed against the section’s own source note. Because Pennsylvania never wrote an office-use provision, it supplies no independent quantity cap, no label legend, no office-use recordkeeping duty and no board-notification duty.

Never describe Pennsylvania as prohibiting office useHigh confidence

There is no Pennsylvania prohibition to cite. The state issued no verdict in either direction; it pointed at federal law. The defensible sentence names the mechanism — no state rule, section 503a governs by reference, and section 503a is patient-specific.

The safe harbour the Board deletedMedium confidence

The Board proposed an express office-use provision in 2017 — proposed § 27.605(a), 47 Pa.B. 1509 — which would have permitted distribution to a medical practitioner to administer where the practitioner could track the product through to an individual patient. It was removed before the rule was finalised. The final-form preamble records that the Board removed the sections to eliminate confusion, would rely instead on the federal reference in § 27.601, and pointed out that section 503a uses the terms "identified individual patient" and "identified patient".Asked the question three ways, the Board struck its own answer and pointed at the federal phrase. That is preamble commentary rather than a rule, and it binds nobody — but it is the Board’s own published statement of how it reads its own regulation, and it is the strongest signal Pennsylvania has produced. See "What this page does not establish" for how far we could re-verify it.

No sterile / non-sterile splitHigh confidence

Section 27.601 names sterile and nonsterile preparations in the same breath and sends both to the same place. Pennsylvania draws no distinction between them on this question.

Nobody can confirm a position with the BoardMedium confidence

The Board is structurally barred from interpreting its own regulations: neither the Board, nor its staff or counsel, may provide legal advice or advisory opinions, including interpretations of the law or regulations. A vendor who says they confirmed an office-use position with the Pennsylvania Board is describing something that cannot happen.

The 5% clause is a licensure exemption, not a permissionMedium confidence

Under 63 P.S. § 391.3(9), in the Wholesale Prescription Drug Distributors License Act, sales of minimal quantities by a retail pharmacy to licensed practitioners for use within their practice are excluded from "wholesale distribution" where they stay under 5% of that pharmacy’s total annual prescription drug sales. It exempts the seller from wholesale distributor licensure. It is measured on the seller’s total sales, it speaks to prescription drugs generally rather than compounded preparations, and it is administered by the Department of Health rather than the Board.It cannot override § 27.601, which independently binds every Pennsylvania pharmacist to section 503a. This clause is the single most quotable-out-of-context provision in the vertical, and it is superficially perfect: it names practitioners, it names their practice, and it carries a tidy number. It still grants no authority to compound anything.

No office-use label legend existsHigh confidence

Pennsylvania has none. Two controlled-substance transfer legends do exist, in different instruments and word-for-word different from each other — one at 49 Pa. Code § 27.18(d)(7) binding the pharmacist on a patient container, one at 35 P.S. § 780-111(f). Neither is an office-use legend, and they must not be merged, paraphrased or repurposed as one.

Nonresident pharmacy — a seam, not a safe harbourLow confidence

Section 390-2(19) of the Pharmacy Act defines a nonresident pharmacy as one shipping into the Commonwealth "pursuant to a prescription order", so an out-of-state pharmacy shipping only non-patient-specific stock arguably never becomes one and the nonresident licensure section never attaches. That does not authorise the shipment. It means the Board’s hook is the wrong hook, and the analysis moves to the Department of Health.

Last changeHigh confidence

None on point. Sections 27.601–27.606 are untouched since 2019, confirmed against the section’s own source note. Every published Pennsylvania Bulletin issue index for 2025 and 2026 to date was parsed for State Board of Pharmacy headings: three final rulemakings landed — pharmacy technician registration, immunization updates, and licensure by endorsement — and none of them touches compounding or office use.Pending and worth watching: General Revisions to 49 Pa. Code Ch. 27 is listed as "Fall 2026, as Proposed" with no compounding content announced. It is the only plausible vehicle for a Pennsylvania office-use rule, and no draft text exists.

Pennsylvania at a glance

Receiving 503B office stock in Pennsylvania

Pennsylvania is this family’s clearest warning that "check the state board of pharmacy" is sometimes wrong advice. An outsourcing facility registers here as a manufacturer with the Department of Health, and the Board of Pharmacy has no role in it — so a reader who checks the Board finds nothing and concludes, wrongly, that Pennsylvania asks for nothing.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Pennsylvania asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inMedium confidence

A manufacturer registration with the Secretary of Health — a Department of Health credential, not a Board of Pharmacy one. 35 P.S. § 780-106(a): "No person shall operate within this Commonwealth as a manufacturer, distributor or retailer of controlled substances, other drugs and devices nor sell, offer for sale nor solicit the purchase of controlled substances, other drugs and devices nor hold them for sale or resale until such person has registered under this act with the secretary." An outsourcing facility is a "manufacturer" here because § 780-102 defines manufacture to include compounding and excludes only the activities of a practitioner. Separate registration is required annually for each place of business; the implementing rules are at 28 Pa. Code §§ 25.113–25.116 and the manufacturer fee is $400 a year.Whether that registration reaches an out-of-state facility with no Pennsylvania location and no Pennsylvania sales representatives is genuinely unresolved — every Pennsylvania hook carries a "within this Commonwealth" limiter. Treat it as an open question and confirm with the Department, never as "nothing is required".

Does your practice need a permit?High confidence

No, and the exclusion is by name. The Health Care Facilities Act at 35 P.S. § 448.802a provides that "The term health care facility shall not include an office used primarily for the private practice of a health care practitioner". 28 Pa. Code § 51.2 licenses seven facility types and "clinic" is not among them, so there is no Pennsylvania analogue to the clinic permits that bite in some other states. And 28 Pa. Code § 25.114(3) exempts "Practitioners licensed by law to prescribe, administer or dispense drugs or devices when operating under the authority of the licensure."That exemption is conduct-based, and the same subsection continues: "Registration is required if practitioners engage in the manufacture or distribution of drugs or devices." Whether a practice moving its own stock between its own non-contiguous Pennsylvania sites is "distribution" is unresolved; if it is, a distributor registration and a set of operating standards attach to it.

Administer vs dispenseMedium confidence

Pennsylvania draws the line in its definitions, and they favour administration: § 780-102 excludes from "prescription" an order dispensed for immediate administration to the ultimate user, and § 780-111(a)–(b) carve out drugs dispensed or administered directly to the patient by a practitioner. The trigger that catches commercial office-stock models is billing. Section 780-112(a) withholds its recordkeeping exemption from a practitioner who is "regularly engaged in charging his patients, whether separately or together with charges for other professional services" for the substances dispensed — so the exemption disappears the moment the practice charges for the drug, whether as a line item or bundled into the visit fee. The § 780-112(b) record of substances administered, dispensed or distributed is unconditional and runs two years.Every provision in this item governs the practitioner’s own conduct downstream. None of them authorises the pharmacy’s upstream non-patient-specific shipment, and treating the first as an answer to the second is the core Pennsylvania error.

Scheduled (controlled) stockHigh confidence

There is no Pennsylvania controlled-substance registration to obtain — DEA registration plus the professional licence is the complete set. Section 780-106(a)(3) exempts practitioners, 28 Pa. Code § 25.114(3) repeats it, and 28 Pa. Code § 25.53(d)(4) requires a controlled-substance prescription to bear the federal DEA registration number: there is no field for a state number because there is no state number. Storage requirements sit at 28 Pa. Code § 25.63. The state prescription monitoring programme defines a dispenser to exclude a person who administers, so an administration-only practice owes it no report.Claiming a credential a state does not issue misleads a reader as badly as omitting one it does. Pennsylvania genuinely has none here.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• Whether an outsourcing facility with no Pennsylvania location and no Pennsylvania sales representatives must register with the Department of Health is not answered by any operative text we could find. Each of the three candidate hooks carries a territorial limiter, and the grammar of the registration command arguably reaches past it. No statute, regulation, guidance, preamble or case resolves it. The honest position is that it is unresolved — confirm with the Department, and never treat it as "not required".
• The Board’s 2019 final-form preamble — the source of the deleted safe harbour and of the "identified individual patient" comment — could not be re-fetched for this page. The Pennsylvania Bulletin’s web interface returns a chrome page rather than the document for the addresses we constructed, so that item is carried from the underlying compliance briefing rather than re-read here. The section’s own source note, which we did verify directly, is what anchors the date and citation.
• The Wholesale Prescription Drug Distributors License Act is served through a JavaScript application that returned only its shell, so the terms of the 5% exclusion are carried from the briefing rather than re-read for this page. Note separately that the Department of Health’s hosted copy of that Act omits a 2024 amendment; the legislature’s text is the one to read.
• We obtained no Department of Health administrative guidance — its drug-program pages failed to return content — so the registration conclusion here rests on statute and regulation alone.
• 28 Pa. Code § 25.131 is captioned as though it binds every dispensing practitioner while its operative text binds pharmacies. Any secondary source that summarises Pennsylvania from section captions will state that rule backwards.
• Search engines were unavailable when this page was researched, so we have not surveyed board newsletters, declaratory statements, enforcement actions, disciplinary orders or coverage of pending bills. Read nothing into that silence — it means we have not looked, not that nothing is there.